Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics CFO Paul Kim reported equity awards and related tax withholdings in company stock. On February 23–24, 2026, he acquired multiple common stock grants tied to time-based and performance-based restricted stock units that vested upon meeting performance milestones from awards granted in 2023, 2024, and 2025.
To satisfy tax withholding obligations triggered by these vestings, shares were withheld at prices around $23 per share rather than sold on the open market. A new restricted stock unit grant will vest over three years, with one-third vesting 12 months after March 1, 2026 and the remainder in quarterly installments, subject to continued service.
Fulgent Genetics, Inc. President and COO Jian Xie reported a mix of stock awards and tax-related share withholdings. On February 24, 2026, he acquired several blocks of common stock at no cost through vested performance-based restricted stock units granted in 2023, 2024, and 2025.
He also received a new grant of 31,962 restricted stock units that vest over three years starting 12 months after March 1, 2026. Shares totaling 3,163, 8,254, 14,751 and 655 were withheld at prices around $23 per share to satisfy tax obligations. Additional indirect holdings are reported in The Hsieh Family Dynasty Trust, where Xie notes only a pecuniary interest.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported equity awards and related tax withholdings in company stock. On February 24, 2026, he acquired 4,891, 12,762, 22,806 and 26,661 shares of common stock at $0 per share through grants and vesting of restricted stock units, including performance-based awards tied to milestones from grants made in 2023, 2024 and 2025.
To cover tax obligations from these vestings, 2,489, 4,661, 8,149 and 403 shares were withheld at prices of about $23.09 and $23.01 per share. After these transactions, Gao directly owned 976,316 to 1,002,977 shares across the reported line items, reflecting routine compensation-related activity rather than open-market buying or selling.
Fulgent Genetics, Inc. director and CEO Ming Hsieh reported multiple equity-related transactions in the company’s common stock. On February 24, 2026, he acquired shares at a price of $0.00 per share through grants and vesting of restricted stock units tied to performance milestones and service-based conditions.
On the same date, shares were also disposed of at $23.09 per share, and on February 23, 2026 at $23.01 per share, to satisfy tax withholding obligations triggered by those vestings, rather than open‑market sales. The filing also shows significant indirect holdings through the Dynasty Trust, The Ming Hsieh Trust, a Uniform Transfers to Minors Act account, and an immediate family member’s account, with varying levels of voting and dispositive power as described in the footnotes.
Fulgent Genetics, Inc. received an amended Schedule 13G/A (Amendment No. 4) reporting institutional ownership of its common stock. Investment entities including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of about 3.0% of the common stock, including 939,375 shares with shared voting and dispositive power for several reporting persons and 918,503 shares for Integrated Core Strategies. The filers certify the shares were not acquired to change or influence control of Fulgent Genetics.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a tax-related share withholding. On January 26, 2026, 1,331 shares of common stock were withheld at $27.53 per share to cover taxes from vested restricted stock units. After this, Gao directly owned 951,559 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax-related share withholding on common stock. On January 26, 2026, 4,711 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations from the vesting of restricted stock units tied to a prior merger agreement.
After this transaction, Xie directly beneficially owns 332,038 common shares. In addition, 220,816 common shares are reported as indirectly owned through The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine tax-related share withholding. On January 26, 2026, 3,004 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations arising from the vesting of previously granted restricted stock units.
After this withholding, Kim beneficially owned 328,146 shares of common stock in direct form. The transaction was coded "F," indicating a tax withholding event linked to equity compensation rather than an open-market sale.
Fulgent Genetics (FLGT) filed a Form 4 reporting that Chief Executive Officer, director and 10% owner Ming Hsieh had 2,116 shares of common stock withheld on 11/23/2025 to cover tax obligations from vesting restricted stock units granted on February 23, 2023. After this withholding, he directly beneficially owns 802,165 common shares. He also has significant indirect holdings, including 7,895,115 shares held by the Dynasty Trust, 220,816 shares held by The Ming Hsieh Trust, and two 1,000-share Uniform Transfers to Minor Act accounts for which he serves as custodian.
Fulgent Genetics (FLGT) reported an insider equity transaction by its Chief Financial Officer and Treasurer, Paul Kim. On 11/23/2025, 671 shares of common stock were withheld at a price of $30 per share to cover tax obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Paul Kim beneficially owned 333,447 shares of Fulgent Genetics common stock directly. This filing documents a routine administrative event related to equity compensation rather than an open-market purchase or sale.